Scientists resurrect ancient cannabis enzymes with medical promise

Researchers at Wageningen University & Research have recreated enzymes from cannabis ancestors millions of years old, revealing how the plant evolved to produce compounds like THC, CBD, and CBC. These ancient enzymes, more flexible than modern versions, show potential for easier biotechnological production of cannabinoids for medical use. The findings, published in Plant Biotechnology Journal, could lead to new medicinal cannabis varieties.

Cannabis plants today produce key cannabinoids—THC, CBD, and CBC—using specialized enzymes, each dedicated to a single compound. A study from Wageningen University & Research demonstrates that this precision emerged through evolution. Early ancestors of cannabis possessed more versatile enzymes capable of generating multiple cannabinoids simultaneously.

To trace this development, the team employed ancestral sequence reconstruction, analyzing DNA from modern plants to predict and rebuild enzymes active millions of years ago. These resurrected enzymes were then synthesized in the lab and tested, providing the first experimental evidence of how cannabinoid biosynthesis originated in a recent cannabis ancestor and refined over time through gene duplications.

The research uncovered practical advantages: the ancient enzymes proved more robust and easier to express in microorganisms like yeast compared to contemporary ones. This could streamline biotechnological manufacturing of cannabinoids, which are increasingly produced outside plants for medical applications.

"What once seemed evolutionarily 'unfinished' turns out to be highly useful," noted lead researcher Robin van Velzen, who collaborated with Cloé Villard. "These ancestral enzymes are more robust and flexible than their descendants, which makes them very attractive starting points for new applications in biotechnology and pharmaceutical research."

Particularly promising is an ancient enzyme that specifically produces CBC, known for anti-inflammatory and analgesic effects. No current cannabis variety naturally yields high CBC levels, so integrating this enzyme could create innovative medicinal strains. The study, detailed in Plant Biotechnology Journal (DOI: 10.1111/pbi.70475), bridges evolutionary biology with potential health benefits.

Awọn iroyin ti o ni ibatan

Illustration of Stellenbosch University researchers discovering rare flavoalkaloids in cannabis leaves under microscope.
Àwòrán tí AI ṣe

Study finds first evidence of rare flavoalkaloids in cannabis leaves

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

Researchers at Stellenbosch University say they have found the first evidence of rare phenolic compounds known as flavoalkaloids in cannabis leaves, after profiling dozens of plant chemicals across three commercially grown strains.

Scientists at the Weizmann Institute of Science in Israel have modified tobacco plants to produce five powerful psychedelic compounds typically found in mushrooms, plants, and toads. The technique uses temporary genetic changes to create a sustainable source for research and potential medicines. Experts say this could simplify production compared to chemical synthesis or harvesting from nature.

Ti AI ṣe iroyin

Researchers at the University of Arizona have found that certain compounds from the cannabis plant can reduce chronic pain in preclinical tests. The terpenes worked in models of fibromyalgia and post-surgical pain without producing psychoactive effects.

Researchers at the John Innes Centre have identified a three-gene system that causes bacteria to burst open, releasing virus-like particles that share DNA, including antibiotic resistance genes. The system, called LypABC, resembles a repurposed bacterial immune defense. The findings, published in Nature Microbiology, highlight how bacteria facilitate horizontal gene transfer.

Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

University of Utah scientists report that a radical SAM enzyme known as PapB can join the ends of certain therapeutic peptides to form stable, ring-shaped structures. In experiments described in ACS Bio & Med Chem Au, the enzyme macrocyclized GLP-1-like peptides—including versions containing nonstandard amino acids found in some modern incretin drugs—an approach the researchers say could help make GLP-1 medicines such as semaglutide (Ozempic and Wegovy) more resistant to breakdown.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ